Cargando…

Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment

Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterised by neutrophilic granulocyte (neutrophil)-filled pustules on the palms and soles. The pathogenesis of PPP is poorly understood. This study conducted an identification of the immune mediators associated with PPP and an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wolk, Kerstin, Wilsmann-Theis, Dagmar, Witte, Katrin, Brembach, Theresa-Charlotte, Kromer, Christian, Gerdes, Sascha, Ghoreschi, Kamran, Reich, Kristian, Mössner, Rotraut, Sabat, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862858/
https://www.ncbi.nlm.nih.gov/pubmed/36674793
http://dx.doi.org/10.3390/ijms24021276
_version_ 1784875194652819456
author Wolk, Kerstin
Wilsmann-Theis, Dagmar
Witte, Katrin
Brembach, Theresa-Charlotte
Kromer, Christian
Gerdes, Sascha
Ghoreschi, Kamran
Reich, Kristian
Mössner, Rotraut
Sabat, Robert
author_facet Wolk, Kerstin
Wilsmann-Theis, Dagmar
Witte, Katrin
Brembach, Theresa-Charlotte
Kromer, Christian
Gerdes, Sascha
Ghoreschi, Kamran
Reich, Kristian
Mössner, Rotraut
Sabat, Robert
author_sort Wolk, Kerstin
collection PubMed
description Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterised by neutrophilic granulocyte (neutrophil)-filled pustules on the palms and soles. The pathogenesis of PPP is poorly understood. This study conducted an identification of the immune mediators associated with PPP and an exploration of apremilast treatment effects on them. We screened for immune mediators elevated in blood taken from 68 patients with PPP versus control participants and included the most promising parameters in the protocol of phase the 2, multicentre study of apremilast (PDE4 inhibitor) in 21 patients with moderate-to-severe PPP (APLANTUS; EudraCT 2016-005122-11) for respective analysis of blood and skin samples of study patients. We investigated stimulated neutrophils and three-dimensional reconstituted epidermis cultures. Interleukin (IL)-19 was found to be the most upregulated immune mediator in the blood of PPP patients. IL-19 serum levels were independent of patients’ age, gender, and BMI but were associated with strongly upregulated cutaneous IL-19 expression and correlated with the number of palmoplantar pustules. In patients participating in the APLANTUS study, apremilast reduced pustules more effectively than erythema and scaling. Moreover, this treatment significantly reduced IL-19 blood and skin levels. The reduction in IL-19 blood levels at week 4 correlated with the reduction in pustule counts at week 20 (end of treatment). IL-19 was expressed by neutrophils activated in vitro and induced CXCL6, a neutrophil-attracting chemokine, in epidermis models. This work demonstrates elevated IL-19 levels in the blood and skin of PPP patients and suggests a relevant role of this cytokine in the appearance of pustules in this disorder. It also suggests the suitability of IL-19 blood levels as a predictive biomarker for the treatment response of PPP patients, which should be validated in further studies.
format Online
Article
Text
id pubmed-9862858
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98628582023-01-22 Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment Wolk, Kerstin Wilsmann-Theis, Dagmar Witte, Katrin Brembach, Theresa-Charlotte Kromer, Christian Gerdes, Sascha Ghoreschi, Kamran Reich, Kristian Mössner, Rotraut Sabat, Robert Int J Mol Sci Article Palmoplantar pustulosis (PPP) is a chronic inflammatory skin disease characterised by neutrophilic granulocyte (neutrophil)-filled pustules on the palms and soles. The pathogenesis of PPP is poorly understood. This study conducted an identification of the immune mediators associated with PPP and an exploration of apremilast treatment effects on them. We screened for immune mediators elevated in blood taken from 68 patients with PPP versus control participants and included the most promising parameters in the protocol of phase the 2, multicentre study of apremilast (PDE4 inhibitor) in 21 patients with moderate-to-severe PPP (APLANTUS; EudraCT 2016-005122-11) for respective analysis of blood and skin samples of study patients. We investigated stimulated neutrophils and three-dimensional reconstituted epidermis cultures. Interleukin (IL)-19 was found to be the most upregulated immune mediator in the blood of PPP patients. IL-19 serum levels were independent of patients’ age, gender, and BMI but were associated with strongly upregulated cutaneous IL-19 expression and correlated with the number of palmoplantar pustules. In patients participating in the APLANTUS study, apremilast reduced pustules more effectively than erythema and scaling. Moreover, this treatment significantly reduced IL-19 blood and skin levels. The reduction in IL-19 blood levels at week 4 correlated with the reduction in pustule counts at week 20 (end of treatment). IL-19 was expressed by neutrophils activated in vitro and induced CXCL6, a neutrophil-attracting chemokine, in epidermis models. This work demonstrates elevated IL-19 levels in the blood and skin of PPP patients and suggests a relevant role of this cytokine in the appearance of pustules in this disorder. It also suggests the suitability of IL-19 blood levels as a predictive biomarker for the treatment response of PPP patients, which should be validated in further studies. MDPI 2023-01-09 /pmc/articles/PMC9862858/ /pubmed/36674793 http://dx.doi.org/10.3390/ijms24021276 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wolk, Kerstin
Wilsmann-Theis, Dagmar
Witte, Katrin
Brembach, Theresa-Charlotte
Kromer, Christian
Gerdes, Sascha
Ghoreschi, Kamran
Reich, Kristian
Mössner, Rotraut
Sabat, Robert
Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment
title Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment
title_full Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment
title_fullStr Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment
title_full_unstemmed Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment
title_short Interleukin-19 Levels Are Increased in Palmoplantar Pustulosis and Reduced following Apremilast Treatment
title_sort interleukin-19 levels are increased in palmoplantar pustulosis and reduced following apremilast treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862858/
https://www.ncbi.nlm.nih.gov/pubmed/36674793
http://dx.doi.org/10.3390/ijms24021276
work_keys_str_mv AT wolkkerstin interleukin19levelsareincreasedinpalmoplantarpustulosisandreducedfollowingapremilasttreatment
AT wilsmanntheisdagmar interleukin19levelsareincreasedinpalmoplantarpustulosisandreducedfollowingapremilasttreatment
AT wittekatrin interleukin19levelsareincreasedinpalmoplantarpustulosisandreducedfollowingapremilasttreatment
AT brembachtheresacharlotte interleukin19levelsareincreasedinpalmoplantarpustulosisandreducedfollowingapremilasttreatment
AT kromerchristian interleukin19levelsareincreasedinpalmoplantarpustulosisandreducedfollowingapremilasttreatment
AT gerdessascha interleukin19levelsareincreasedinpalmoplantarpustulosisandreducedfollowingapremilasttreatment
AT ghoreschikamran interleukin19levelsareincreasedinpalmoplantarpustulosisandreducedfollowingapremilasttreatment
AT reichkristian interleukin19levelsareincreasedinpalmoplantarpustulosisandreducedfollowingapremilasttreatment
AT mossnerrotraut interleukin19levelsareincreasedinpalmoplantarpustulosisandreducedfollowingapremilasttreatment
AT sabatrobert interleukin19levelsareincreasedinpalmoplantarpustulosisandreducedfollowingapremilasttreatment